Brainstorm Cell Therapeutics Inc. (BCLI) EPS Estimated At $-0.14; Shorts at Fastenal Company (FAST) Lowered By 3.13%

April 17, 2018 - By Linda Rogers

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Logo

Fastenal Company (NASDAQ:FAST) had a decrease of 3.13% in short interest. FAST’s SI was 27.76M shares in April as released by FINRA. Its down 3.13% from 28.66M shares previously. With 2.84M avg volume, 10 days are for Fastenal Company (NASDAQ:FAST)’s short sellers to cover FAST’s short positions. The SI to Fastenal Company’s float is 9.69%. The stock decreased 0.28% or $0.14 during the last trading session, reaching $50.53. About 2.15M shares traded. Fastenal Company (NASDAQ:FAST) has risen 5.62% since April 17, 2017 and is uptrending. It has underperformed by 5.93% the S&P500.

Analysts expect Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) to report $-0.14 EPS on May, 21.They anticipate $0.04 EPS change or 40.00% from last quarter’s $-0.1 EPS. After having $0.02 EPS previously, Brainstorm Cell Therapeutics Inc.’s analysts see -800.00% EPS growth. The stock increased 1.49% or $0.05 during the last trading session, reaching $3.4. About 46,361 shares traded. Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) has declined 23.19% since April 17, 2017 and is downtrending. It has underperformed by 34.74% the S&P500.

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders that include amyotrophic lateral sclerosis, multiple sclerosis, Parkinson's disease, and others. The company has market cap of $64.84 million. The firm holds rights to develop and commercialize its NurOwn technology through a licensing agreement with Ramot of Tel Aviv University Ltd. It currently has negative earnings. The Company’s NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release various neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons.

Since December 15, 2017, it had 0 insider purchases, and 4 insider sales for $2.06 million activity. Jansen James C also sold $14,036 worth of Fastenal Company (NASDAQ:FAST) on Friday, March 9. Polipnick Gary A. also sold $140,793 worth of Fastenal Company (NASDAQ:FAST) shares. The insider Miller Charles S. sold $1.48M. Drazkowski William Joseph had sold 7,500 shares worth $424,808.

Among 19 analysts covering Fastenal (NASDAQ:FAST), 10 have Buy rating, 1 Sell and 8 Hold. Therefore 53% are positive. Fastenal had 77 analyst reports since July 21, 2015 according to SRatingsIntel. Stephens maintained it with “Buy” rating and $62.0 target in Wednesday, January 17 report. The stock has “Buy” rating by Stephens on Friday, June 2. On Friday, March 2 the stock rating was maintained by Northcoast with “Buy”. Stifel Nicolaus maintained the shares of FAST in report on Thursday, July 13 with “Hold” rating. The company was maintained on Wednesday, January 17 by Robert W. Baird. Credit Suisse upgraded the stock to “Outperform” rating in Wednesday, April 19 report. The firm earned “Hold” rating on Tuesday, August 25 by William Blair. The rating was downgraded by Robert W. Baird to “Neutral” on Monday, August 24. The stock of Fastenal Company (NASDAQ:FAST) earned “Neutral” rating by Susquehanna on Thursday, August 27. Stifel Nicolaus maintained Fastenal Company (NASDAQ:FAST) rating on Thursday, March 17. Stifel Nicolaus has “Buy” rating and $51 target.

Investors sentiment decreased to 1.05 in 2017 Q4. Its down 0.25, from 1.3 in 2017Q3. It dived, as 37 investors sold Fastenal Company shares while 215 reduced holdings. 91 funds opened positions while 174 raised stakes. 232.28 million shares or 0.94% less from 234.48 million shares in 2017Q3 were reported. Moreover, Stock Yards State Bank Co has 0.03% invested in Fastenal Company (NASDAQ:FAST). State Street invested in 11.74M shares. Zebra Mgmt Llc invested in 27,287 shares or 0.51% of the stock. Mairs And, Minnesota-based fund reported 2.98M shares. 67,320 are owned by Long Road Inv Counsel Ltd Co. 76,566 were accumulated by Hendershot Investments Inc. Cambridge Invest Research Advisors has invested 0.02% in Fastenal Company (NASDAQ:FAST). Citigroup holds 0% of its portfolio in Fastenal Company (NASDAQ:FAST) for 98,083 shares. Nottingham Advsr stated it has 15,700 shares. Advisory Svcs Limited Company has 19,821 shares for 0.09% of their portfolio. Hengehold Capital Management Limited stated it has 0.06% of its portfolio in Fastenal Company (NASDAQ:FAST). D E Shaw & reported 0.01% in Fastenal Company (NASDAQ:FAST). Check Capital Ca invested 0.42% in Fastenal Company (NASDAQ:FAST). Moreover, Ontario Teachers Pension Plan Board has 0.04% invested in Fastenal Company (NASDAQ:FAST) for 57,911 shares. 1.37 million were accumulated by Amundi Pioneer Asset Inc.

Fastenal Company (NASDAQ:FAST) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: